Palbociclib slows mesothelioma cells but fake senescence leaves senolytics powerless
In lab-grown mesothelioma cells, palbociclib arrest was reversible and senolytic combinations failed, while cisplatin produced durable senescence.
Summary
Palbociclib, a CDK4/6 inhibitor, stops pleural mesothelioma cells from dividing and makes them look senescent: bigger, SA-β-galactosidase positive, and secreting IL-6 and IL-8. But this was a mask. When the drug was removed, the cells shrank, lost the markers and regrew. Because the cells were not truly senescent, senolytic strategies had little to attack. Bcl-xL, Bcl-2 and Mcl-1 inhibitors, plus Src, JAK and mTOR inhibitors, did not add killing to palbociclib. Cisplatin, by contrast, produced durable arrest with sustained senescence markers and DNA damage signals. All of this was done in cultured cell lines, so it shows no human outcomes. It does suggest that senescence-like markers alone cannot tell you whether a senolytic will work.
Detailed Summary
Senolytics are drugs meant to clear senescent cells, and a popular cancer idea is to push tumor cells into senescence with a CDK4/6 inhibitor and then eliminate them. Pleural mesothelioma is an aggressive asbestos-linked cancer with few options, and most tumors lose CDKN2A (p16), which may predict sensitivity to CDK4/6 inhibitors. This in vitro study asked whether palbociclib-induced senescence in mesothelioma cells can be exploited with senolytics.
The team treated four mesothelioma lines (H28, H2452, ICO_MPM2, ICO_MPM3), with MCF7 and A549 as non-mesothelioma comparators, using palbociclib near the clinical Cmax (0.1 to 0.5 µM) for 15 days. Proliferation fell, cells enlarged, SA-β-Gal rose, and IL-6 and IL-8 increased dose-dependently. Cell death reached at most about 40% at 0.5 µM, and was minimal in ICO_MPM3. After withdrawal on day 30, most lines regrew, lost enlargement, SA-β-Gal and cytokine output, and stayed sensitive to re-treatment.
All lines expressed Bcl-xL, while Bcl-2, Mcl-1 and Bcl-W varied. Palbociclib raised Bcl-xL and Bcl-W in H28 within 72 hours, but changes were not significant in primary lines at 3 to 7 days. Navitoclax and A-1331852 killed cells that were intrinsically Bcl-xL dependent, but palbociclib added little beyond additivity in H28, H2452 and H226, and H2452 and H226 were resistant when treatment was sequential. Venetoclax and S63845 were largely ineffective, apart from a slight venetoclax effect in MSTO-211H.
A phospho-kinase array showed palbociclib increased phosphorylation of Src, STAT3 and mTOR. Yet dasatinib, momelotinib and Torin-1 did not synergize, nor did metformin or the IRE1α inhibitor MKC8866. Even 5 µM palbociclib, ten times higher, did not produce permanent arrest. Cisplatin did: at sub-Cmax doses (below 14.4 µM) for 3 days, cells did not regrow, counts fell further after washout, and death stayed mostly under about 40%, indicating a cytostatic effect. Enlargement, SA-β-Gal and SASP persisted or rose, and phospho-γH2AX and p21 stayed elevated.
Sorting by size and SA-β-Gal activity in H28 and ICO_MPM2 settled the question. Palbociclib-treated cells regrew whether they were large or small and SA-β-Gal high or low, while almost no cisplatin-pretreated sorted cells regrew. Palbociclib's γH2AX and p21 changes were modest and reversed on withdrawal. The authors conclude that palbociclib induces a reversible, pseudo-senescent arrest, not bona fide senescence.
The implication is that markers like cell size, SA-β-Gal and IL-6/IL-8 can mislead, and senolytic strategies depend on confirming irreversibility. These are cell-line experiments, some with small replicate numbers, with no animal or human data. Palbociclib was shown to be cytostatic and reversible here; whether senolytic pairings work in vivo, or at higher doses, was not tested.
Key Findings
- Palbociclib (0.1 to 0.5 µM) caused cell enlargement, higher SA-β-Gal and dose-dependent IL-6/IL-8 in all four mesothelioma lines, but these reversed after drug removal and cells regrew.
- Palbociclib caused at most about 40% cell death at 0.5 µM, with minimal death in ICO_MPM3, so the effect was mainly cytostatic.
- Bcl-xL inhibitors (navitoclax, A-1331852) killed Bcl-xL-dependent lines, but palbociclib pretreatment added at most an additive effect; H2452 and H226 were resistant when given sequentially.
- Venetoclax (Bcl-2) and S63845 (Mcl-1) showed no meaningful synergy, except a slight venetoclax effect in MSTO-211H.
- Palbociclib raised phospho-Src, STAT3 and mTOR, but dasatinib, momelotinib, Torin-1, metformin and MKC8866 did not synergize.
- Cisplatin below 14.4 µM gave no regrowth after washout, with sustained SASP, γH2AX and p21; palbociclib's markers reversed.
- Sorted palbociclib-treated cells regrew regardless of size or SA-β-Gal status, while almost no cisplatin-pretreated cells regrew.
Methodology
In vitro study using four mesothelioma lines (two commercial, two patient-derived), with MCF7 and A549 comparators. Readouts were cell counts, PI viability, crystal violet, SA-β-Gal, IL-6/IL-8 secretion, western blots, a phospho-kinase array, and flow cytometry for γH2AX and p21. Treatments were concurrent or sequential, with washout and regrowth assays plus spectral-cytometry single-cell sorting. Replicates were typically N=2 to 5, analyzed by ANOVA with multiple comparisons.
Study Limitations
Findings come only from cultured cell lines, with some small replicate numbers (N=2 in places) and difficulty scoring SA-β-Gal in high-confluence or intrinsically positive lines. Only a limited set of senolytic and pathway inhibitors was tested, and no in vivo, immune or higher-dose palbociclib combination work was done. Conflicts of interest were not stated in the provided text, which was truncated in the Discussion.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
